Hadrian Holder
Family Medicine · New Haven, CTNPI 1083093181
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Viiv Healthcare Company at 49.2% of the total. Reporting peaked in 2024 at $13,201 and has fallen 50.7% since, to $6,505 in 2025. Among family medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 408 payments — averaging $53.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$11K
- Gilead$8K
- AbbVie$620
- AstraZeneca$419
- GSK$380
- Novo Nordisk$315
- plus $1K from 16 others
Across 34 payments — averaging $5697.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$194K
What the payments were for
- Consulting fees$8,10037%
- Travel & lodging$5,86827%
- Food & beverage$7,73636%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 146 | $10,678 |
| Gilead | 102 | $7,839 |
| AbbVie | 42 | $620 |
| AstraZeneca | 14 | $419 |
| GSK | 11 | $380 |
| Novo Nordisk | 16 | $315 |
| Merck | 11 | $308 |
| Kowa Pharmaceuticals America, Inc. | 26 | $256 |
| Phathom Pharmaceuticals, Inc. | 1 | $124 |
| Pfizer | 6 | $124 |
| Boehringer Ingelheim | 6 | $113 |
| Theratechnologies Inc. | 4 | $91 |
| Exact Sciences | 5 | $85 |
| Ardelyx, Inc. | 3 | $65 |
| Amgen | 4 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $53 |
| Lundbeck LLC | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Lilly USA, LLC | 2 | $35 |
| Johnson & Johnson | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,704 in reported general payments places this provider in the 95th percentile of 588 family medicine providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 194 | $789,536 |
| JardianceEmpagliflozin | 65 | $68,206 |
| OzempicSemaglutide | 58 | $62,770 |
| RybelsusSemaglutide | 16 | $44,314 |
| LinzessLinaclotide | 45 | $35,245 |
| PifeltroDoravirine | 17 | $32,751 |
| TradjentaLinagliptin | 36 | $32,374 |
| TrulicityDulaglutide | 24 | $27,437 |
| IsentressRaltegravir Potassium | 12 | $23,548 |
| EliquisApixaban | 29 | $21,609 |
| FarxigaDapagliflozin Propanediol | 13 | $19,487 |
| JanuviaSitagliptin Phosphate | 18 | $18,690 |
| XareltoRivaroxaban | 13 | $14,451 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $11,512 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,704 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $7,839 | $789,536194 claims |
| Novo NordiskOzempic, Rybelsus | $315 | $107,08474 claims |
| Boehringer IngelheimJardiance, Tradjenta | $113 | $100,580101 claims |
| MerckPifeltro, Isentress, Januvia, Janumet | $308 | $86,50062 claims |
| AbbVieLinzess | $620 | $35,24545 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $380 | $27,87882 claims |
| Lilly USA, LLCTrulicity | $35 | $27,43724 claims |
| AstraZenecaFarxiga, Symbicort | $419 | $26,46743 claims |
| PfizerEliquis | $124 | $21,60929 claims |
| Johnson & JohnsonXarelto | $19 | $14,45113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family medicine providers in Connecticut.
Other family medicine in New Haven
- Nicholas TzikasNew Haven$46K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Helar CamposNew London$29K
- Kristin GianniniVernon$28K
- Sanjeev RaoBridgeport$27K
- Michael BeyVernon Rockville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.